Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Seeks Partners For Biosimilars And Oncology Research

FY22 Guidance Lowered

Executive Summary

Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.

You may also be interested in...



Lupin Expands US Inhalation Business With Two Sunovion Brands

Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.

Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Glenmark Fulfills Promise To Introduce Tiotropium In Europe

India’s Glenmark had noted recently that market entry was forthcoming for a generic Boehringer Ingelheim’s Spiriva Handihaler, and has now delivered with an initial UK launch.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel